Department of Psychiatry, School of Medicine, Dokkyo Medical University, Tochigi, Japan.
Neuropsychopharmacol Rep. 2022 Sep;42(3):391-394. doi: 10.1002/npr2.12280. Epub 2022 Jun 24.
Although resistance to thyroid hormone beta (RTHβ) is associated with attention-deficit/hyperactivity disorder, there are few reports of other concomitant mood disorders in individuals with RTHβ.
A 67-year-old woman who had been previously diagnosed with RTHβ (Refetoff syndrome) came to our department as a depressed patient. She was hospitalized twice for depression and treated with antidepressants both times. Paroxetine (37.5 mg/day) treatment during the first hospitalization did not cause any side effects, but treatment with mirtazapine (15 mg/day) and venlafaxine (150 mg/day) during the second hospitalization caused clonus and disturbance of consciousness, and these adverse effects resulted in a prolonged period of hospitalization. Finally, the patient's symptoms were controlled with quetiapine (75 mg/day).
Poor tolerability to antidepressants was observed, which may be related to thyroid hormone intolerance. Low doses of quetiapine may contribute to improvements in depression.
尽管甲状腺激素β(TRHβ)抵抗与注意力缺陷/多动障碍有关,但 TRHβ 患者同时伴有其他情绪障碍的报道很少。
一名 67 岁女性,此前被诊断为 TRHβ(Refetoff 综合征),因抑郁来我院就诊。她曾两次因抑郁住院,两次均接受抗抑郁治疗。第一次住院期间,帕罗西汀(37.5mg/天)治疗没有引起任何副作用,但第二次住院期间使用米氮平(15mg/天)和文拉法辛(150mg/天)治疗时出现了阵挛和意识障碍,这些不良反应导致住院时间延长。最后,患者的症状用喹硫平(75mg/天)得到控制。
观察到抗抑郁药的耐受性差,这可能与甲状腺激素不耐受有关。喹硫平的低剂量可能有助于改善抑郁。